drugset / Trial / NCT02827890
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.
Timeline
- Start
- 2016-04
- Primary completion
- 2016-04
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lobeglitazone | Small molecule | 0.5 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |